Biotech Values

[DewDiligence]

DNDN – The most astonishing thing about the entire Provenge saga is that, after all these years, the program’s very existence is teetering on the precipice.

Imagine how different things would be now if 9902b had been massively overpowered by taking into account program-survival bias. A Big Pharma partner would undoubtedly have done exactly that by designing 9902b to be at least 1.5x bigger and perhaps as much as 2x bigger than the size DNDN settled on.

Instead, short-sellers have made a lot of money on DNDN over the past several years. It was an easy bet for them to make given the sorry track record of small-biotech CEO’s who think they know it all and don’t need the help of an experienced partner.